Inhibition of the L-arginine-nitric oxide pathway mediates the antidepressant effects of ketamine in rats in the forced swimming test

Pharmacology Biochemistry and Behavior

Volumn 110, Issue , 2013, Pages 8-12

  Zhang, Guang Fen ^a   Wang, Nan ^a   Shi, Jin Yun ^a   Xu, Shi Xia ^a   Li, Xiao Min ^a   Ji, Mu Huo ^a   Zuo, Zhi Yi ^b   Zhou, Zhi Qiang ^a   Yang, Jian Jun ^a  

^a NANJING UNIVERSITY   (China)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Depression; Ketamine; L arginine; Nitric oxide synthase; Rats

Indexed keywords

ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; KETAMINE; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMOBILITY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

RATTUS;

DEPRESSION; KETAMINE; L-ARGININE; NITRIC OXIDE SYNTHASE; RATS;

ANIMALS; ANTIDEPRESSIVE AGENTS; ARGININE; KETAMINE; MALE; NITRIC OXIDE; RATS; RATS, WISTAR; STRESS, PHYSIOLOGICAL; SWIMMING;

EID: 84882787934     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.05.010     Document Type: Article

References (44)

1. Almeida RC, Felisbino CS, Lopez MG, Rodrigues AL, Gabilan NH. Evidence for the involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. Behav Brain Res 2006;168: 318-22. (Pubitemid 43201950)
2. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011;475: 91-5.
3. Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 2011;16: 1068-70.
4. Chaviaras S, Mak P, Ralph D, Krishnan L, Broadbear JH. Assessing the antidepressantlike effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. Psychopharmacology (Berl) 2010;210: 35-43.
5. da Silva GD, Matteussi AS, dos Santos AR, Calixto JB, Rodrigues AL. Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. Neuroreport 2000;11: 3699-702.
6. de Oliveira L, Fraga DB, De Luca RD, Canever L, Ghedim FV, Matos MP, et al. Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine. Metab Brain Dis 2011;26: 69-77.
7. de Oliveira RM, Aparecida Del Bel E, Mamede-Rosa ML, Padovan CM, Deakin JF, Guimaraes FS. Expression of neuronal nitric oxide synthase mRNA in stressrelated brain areas after restraint in rats. Neurosci Lett 2000;289: 123-6. (Pubitemid 30440641)
8. De Vry J, Schreiber R, Melon C, Dalmus M, Jentzsch KR. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur Neuropsychopharmacol 2004;14: 487-95. (Pubitemid 39626897)
9. Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995;121: 66-72.
10. Dhir A, Kulkarni SK. Nitric oxide and major depression. Nitric Oxide 2011;24: 125-31.
11. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012;338: 68-72.
12. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012;35: 47-56.
13. Ergun Y, Ergun UG. Prevention of pro-depressant effect of L-arginine in the forced swim test by NG-nitro-L-arginine and [1H-[1,2,4]Oxadiazole[4,3-a] quinoxalin-1-one]. Eur J Pharmacol 2007;554: 150-4. (Pubitemid 44879408)
14. Esplugues JV. NO as a signalling molecule in the nervous system. Br J Pharmacol 2002;135: 1079-95. (Pubitemid 34259107)
15. Ferreira FR, Oliveira AM, Dinarte AR, Pinheiro DG, Greene LJ, Silva Jr WA, et al. Changes in hippocampal gene expression by 7-nitroindazole in rats submitted to forced swimming stress. Genes Brain Behav 2012;11: 303-13.
16. Galley HF, Webster NR. Brain nitric oxide synthase activity is decreased by intravenous anesthetics. Anesth Analg 1996;83: 591-4. (Pubitemid 26296372)
17. Garcia LS, Comim CM, Valvassori SS, Reus GZ, Barbosa LM, Andreazza AC, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2008;32: 140-4.
18. Harkin A, Connor TJ, Walsh M, St John N, Kelly JP. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2003;44: 616-23. (Pubitemid 36369141)
19. Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG, et al. Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35: 1155-9.
20. Karolewicz B, Paul IA, Antkiewicz-Michaluk L. Effect of NOS inhibitor on forced swim test and neurotransmitters turnover in themouse brain. Pol J Pharmacol 2001;53: 587-96.
21. Karolewicz B, Szebeni K, Stockmeier CA, Konick L, Overholser JC, Jurjus G, et al. Low nNOS protein in the locus coeruleus in major depression. J Neurochem 2004;91: 1057-66. (Pubitemid 39587444)
22. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289: 3095-105. (Pubitemid 37432885)
23. Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011;224: 107-11.
24. Krass M, Wegener G, Vasar E, Volke V. The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2011;218: 57-63.
25. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329: 959-64.
26. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011;69: 754-61.
27. Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino- 3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63: 349-52. (Pubitemid 351146651)
28. Mantovani M, Pertile R, Calixto JB, Santos AR, Rodrigues AL. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway. Neurosci Lett 2003;343: 1-4. (Pubitemid 36577198)
29. Monteggia LM, Gideons E, Kavalali ET. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 2013;73: 1199-203.
30. Moretti M, Freitas AE, Budni J, Fernandes SC, Balen Gde O, Rodrigues AL. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test. Behav Brain Res 2011;225: 328-33.
31. Noda Y, Mouri A, Waki Y, Nabeshima T. Development of animal models for schizophrenia based on clinical evidence: expectation for psychiatrists. Nihon Shinkei Seishin Yakurigaku Zasshi 2009;29: 47-53.
32. Oliveira RM, Guimaraes FS, Deakin JF. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008;41: 333-41. (Pubitemid 351761067)
33. Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) 2005;177: 245-55. (Pubitemid 40137284)
34. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266: 730-2. (Pubitemid 8073804)
35. Pozo D, Reiter RJ, Calvo JR, Guerrero JM. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. J Cell Biochem 1997;65: 430-42. (Pubitemid 27190697)
36. Romero TR, Galdino GS, Silva GC, Resende LC, Perez AC, Cortes SF, et al. Ketamine activates the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway to induce peripheral antinociception in rats. Anesth Analg 2011;113: 1254-9.
37. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007;113: 134-53. (Pubitemid 46017069)
38. Shimaoka M, Iida T, Ohara A, Taenaka N, Mashimo T, Honda T, et al. Ketamine inhibits nitric oxide production in mouse-activated macrophage-like cells. Br J Anaesth 1996;77: 238-42. (Pubitemid 26254513)
39. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009;30: 563-9.
40. Spiacci Jr A, Kanamaru F, Guimaraes FS, Oliveira RM. Nitric oxide-mediated anxiolyticlike and antidepressant-like effects in animal models of anxiety and depression. Pharmacol Biochem Behav 2008;88: 247-55. (Pubitemid 350119843)
41. Yildiz F, Erden BF, Ulak G, Utkan T, Gacar N. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology (Berl) 2000;149: 41-4. (Pubitemid 30187365)
42. Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71: 939-46.
43. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63: 856-64. (Pubitemid 44188478)
44. Zhao X, Venkata SL, Moaddel R, Luckenbaugh DA, Brutsche NE, Ibrahim L, et al. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol 2012;74: 304-14.